Methylhydroxynandrolone
Methylhydroxynandrolone, also known as 4-hydroxy-17α-methyl-19-nortestosterone, as well as 4,17β-dihydroxy-17α-methylestr-4-en-3-one, is a synthetic, orally active anabolic–androgenic steroid and a 17α-alkylated derivative of nandrolone which was never marketed. It was first described in 1964 and was studied in the treatment of breast cancer, but was not introduced for clinical use. The drug re-emerged in 2004 when it started being sold on the Internet as a "dietary supplement". MOHN joined other AAS as a controlled substance in the United States on 20 January 2005.
MOHN is non-aromatizable due to the presence of a hydroxy group at the C4 position, and for this reason, poses no risk of estrogenic side effects like gynecomastia at any dosage, unlike many other AAS. 5α-Reduction is also inhibited by the C4 hydroxy group of MOHN and, because of this, MOHN may have a relatively higher ratio of androgenic to anabolic activity than other nandrolone derivatives. Early assays found that MOHN had approximately 13 times the anabolic activity and 3 times the androgenic activity of methyltestosterone.
MOHN is the 4-hydroxylated derivative of normethandrone, the 17α-methylated derivative of oxabolone, the 4-hydroxylated and 17α-methylated derivative of nandrolone, and the 19-demethylated analogue of oxymesterone.
